Install
News of the Day Anticipated therapies and not-so-anticipated dominate July PBAC agenda GSK brings Melbourne discovered treatment 'home' to Australian patients New government report reveals the emerging impact of generational reform Health department quietly launches major review of blood products supply Budget reveals
- 219articles · 365d
- 2+ day agolatest article
- Jan 21, 2026earliest in window
- 90%with images
- 159avg words
- Medical 203
- Health 153
- Health & Wellness 146
- Business & Industrial 71
- Economy, Business & Finance 32
- Science & Technology 23
- Finance & Business 12
- Education 3
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
TGA approves GSK's six‑monthly treatment for severe eosinophilic asthma and nasal polyps - BioPharmaDispatch
1+ mon, 2+ week ago (138+ words) TGA approves GSK's six‑monthly treatment for severe eosinophilic asthma and nasal polyps PharmaDispatch TGA approves GSK's six‑monthly treatment for severe eosinophilic asthma and nasal polyps Professor Jo Douglass, specialist physician and Professor of Medicine at the University of…...
Reform for patients the focus of private cancer physicians summit
1+ mon, 2+ week ago (107+ words) PharmaDispatch Reform for patients the focus of private cancer physicians summit The 2026 PCPA Cancer Summit will bring together leading cancer specialists, policymakers, patient advocates and industry partners in Melbourne on 28 and 29 August to explore solutions to improving access to treatment....
Early clinical imaging shows Syntara candidate reduces brain inflammation in people at high risk of Parkinson’s
2+ mon, 1+ week ago (140+ words) PharmaDispatch Early clinical imaging shows Syntara candidate reduces brain inflammation in people at high risk of Parkinson’s Australian company Syntara and Parkinson’s Research Ventures have reported early signs that a novel anti-inflammatory candidate may reduce brain inflammation in people at…...
Widespread use of statins narrows heart-risk gap between overweight and normal-weight adults
2+ mon, 1+ week ago (150+ words) PharmaDispatch Widespread use of statins narrows heart-risk gap between overweight and normal-weight adults A major international study has found that obese middle-aged and older adults now face a similar risk of heart attack to that of their slimmer and healthy…...
Australia approves first in class therapy for chronic graft versus host disease
4+ mon, 1+ week ago (135+ words) PharmaDispatch Australia approves first in class therapy for chronic graft versus host disease Specialised Therapeutics secured the rights to NIKTIMVO in Australia, New Zealand, and Singapore via a June 2025 agreement with Incyte. The company said it is exploring reimbursement through…...
Lilly therapy approved in Australia as first non-covalent BTK inhibitor for common blood cancer
4+ mon, 1+ week ago (157+ words) PharmaDispatch Lilly therapy approved in Australia as first non-covalent BTK inhibitor for common blood cancer “We acknowledge there are significant challenges involved in securing reimbursement for innovative medicines in Australia, and our focus in the near term is on enabling…...
Radiopharm reports strong interim results for brain metastases imaging agent
5+ mon, 2+ week ago (129+ words) PharmaDispatch Radiopharm reports strong interim results for brain metastases imaging agent Radiopharm Theranostics has reported encouraging interim results from its ongoing Phase 2b clinical trial of RAD 101, an experimental imaging agent designed to improve the detection of recurrent brain metastases. … Pharmacy…...
Regulators clear path for pivotal trial of PYC vision therapy for rare blinding disease
5+ mon, 3+ week ago (150+ words) PharmaDispatch Regulators clear path for pivotal trial of PYC vision therapy for rare blinding disease The Perth and San Francisco-based biotechnology company announced that discussions with the FDA confirmed key elements of the clinical trial required to support a future…...
Implantable sensor approved in Australia could transform how hydrocephalus is monitored
5+ mon, 3+ week ago (153+ words) PharmaDispatch Implantable sensor approved in Australia could transform how hydrocephalus is monitored A coin-sized implantable sensor designed to monitor pressure inside the brain has been approved for use in Australia, offering clinicians a new way to manage hydrocephalus and potentially…...
Royal visit highlights new collaborations targeting obesity and liver disease
5+ mon, 3+ week ago (132+ words) PharmaDispatch Royal visit highlights new collaborations targeting obesity and liver disease Two new health collaborations unveiled at Parliament House in Canberra during the State Visit of Their Majesties King Frederik X and Queen Mary of Denmark signal a growing effort…...